SERA 7.67 Sera Prognostics, Inc.
| Range: | 1.56-12.355 | Vol Avg: | 104085 | Last Div: | 0 | Changes: | -0.04 |
| Beta: | 1.03 | Cap: | 0.25B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Jul 15 2021 | Empoloyees: | 55 | ||
| CUSIP: | 81749D107 | CIK: | 0001534969 | ISIN: | US81749D1072 | Country: | US |
| CEO: | Ms. Evguenia Lindgardt M.B.A. | Website: | https://seraprognostics.com | ||||
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow